Eton Pharmaceuticals (ETON) Revenue & Revenue Breakdown
Eton Pharmaceuticals Revenue Highlights
Latest Revenue (Y)
$31.64M
Latest Revenue (Q)
$9.07M
Main Segment (Y)
Product Sales and Royalties
Eton Pharmaceuticals Revenue by Period
Eton Pharmaceuticals Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $31.64M | 48.90% |
| 2022-12-31 | $21.25M | -2.66% |
| 2021-12-31 | $21.83M | 55879.49% |
| 2020-12-31 | $39.00K | -95.93% |
| 2019-12-31 | $959.00K | 100.00% |
| 2018-12-31 | - | - |
Eton Pharmaceuticals generated $31.64M in revenue during NA 2023, up 48.90% compared to the previous quarter, and up Infinity% compared to the same period a year ago.
Eton Pharmaceuticals Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | $9.07M | 13.91% |
| 2024-03-31 | $7.97M | 8.93% |
| 2023-12-31 | $7.31M | 4.06% |
| 2023-09-30 | $7.03M | -41.42% |
| 2023-06-30 | $12.00M | 126.19% |
| 2023-03-31 | $5.30M | -37.59% |
| 2022-12-31 | $8.50M | 164.00% |
| 2022-09-30 | $3.22M | -56.25% |
| 2022-06-30 | $7.36M | 238.14% |
| 2022-03-31 | $2.18M | -64.29% |
| 2021-12-31 | $6.09M | 686.19% |
| 2021-09-30 | $775.00K | -74.73% |
| 2021-06-30 | $3.07M | -74.22% |
| 2021-03-31 | $11.90M | 14587.65% |
| 2020-12-31 | $81.00K | -150.31% |
| 2020-09-30 | $-161.00K | -905.00% |
| 2020-06-30 | $20.00K | -79.80% |
| 2020-03-31 | $99.00K | -78.43% |
| 2019-12-31 | $459.00K | 100.00% |
| 2019-09-30 | - | 100.00% |
| 2019-06-30 | - | -100.00% |
| 2019-03-31 | $500.00K | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2018-09-30 | - | 100.00% |
| 2018-06-30 | - | 100.00% |
| 2018-03-31 | - | 100.00% |
| 2017-12-31 | - | 100.00% |
| 2017-09-30 | - | 100.00% |
| 2017-06-30 | - | - |
Eton Pharmaceuticals generated $9.07M in revenue during Q2 2024, up 13.91% compared to the previous quarter, and up 171.08% compared to the same period a year ago.
Eton Pharmaceuticals Revenue Breakdown
Eton Pharmaceuticals Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 23 | Dec 22 | Dec 21 | Dec 19 |
|---|---|---|---|---|
| License | $5.50M | - | - | - |
| Product Sales and Royalties | $26.14M | - | - | - |
| Licensing Revenue | - | $10.00M | $19.00M | $500.00K |
Eton Pharmaceuticals's latest annual revenue breakdown by segment (product or service), as of Dec 23: Product Sales and Royalties (82.62%), and License (17.38%).
Quarterly Revenue by Product
| Product/Service | Mar 24 | Dec 22 | Jun 22 | Dec 21 | Jun 21 | Mar 21 |
|---|---|---|---|---|---|---|
| License | - | - | - | - | - | - |
| Product Sales and Royalties | $7.97M | - | - | - | - | - |
| Licensing Revenue | - | $5.00M | $5.00M | $5.00M | $2.50M | $11.50M |
| Royalty Revenue | - | - | - | - | - | $143.00K |
Eton Pharmaceuticals's latest quarterly revenue breakdown by segment (product or service), as of Mar 24: Product Sales and Royalties (100.00%).
Eton Pharmaceuticals Revenue Breakdown by Country
Quarterly Revenue by Country
| Country | Dec 22 | Jun 22 | Dec 21 | Jun 21 | Mar 21 |
|---|---|---|---|---|---|
| Licensing Revenue | $5.00M | $5.00M | $5.00M | $2.50M | $11.50M |
| Royalty Revenue | - | - | - | - | $143.00K |
Eton Pharmaceuticals's latest quarterly revenue breakdown by geography, as of Dec 22: Licensing Revenue (100.00%).
Eton Pharmaceuticals Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| TVTX | Travere Therapeutics | $145.24M | $54.12M |
| ALEC | Alector | $97.06M | $15.89M |
| ETON | Eton Pharmaceuticals | $31.64M | $9.07M |
| TARS | Tarsus Pharmaceuticals | $17.45M | $40.81M |
| KRON | Kronos Bio | $6.29M | $2.69M |
| INBX | Inhibrx | $1.80M | - |
| LYRA | Lyra Therapeutics | $1.56M | $598.00K |
| LIAN | LianBio | - | - |
| BDTX | Black Diamond Therapeutics | - | - |
| ALDX | Aldeyra Therapeutics | - | - |
| GOSS | Gossamer Bio | - | $95.84M |
| CNTB | Connect Biopharma | - | - |
| ABOS | Acumen Pharmaceuticals | - | - |
| REPL | Replimune Group | - | - |
| PASG | Passage Bio | - | - |
| ELYM | Eliem Therapeutics | - | - |
| CELC | Celcuity | - | - |
| MACK | Merrimack Pharmaceuticals | - | - |
| NVCT | Nuvectis Pharma | - | - |
| ELVN | Enliven Therapeutics | - | - |
| NUVB | Nuvation Bio | - | $1.44M |
| ELDN | Eledon Pharmaceuticals | - | - |
ETON Revenue FAQ
What is Eton Pharmaceuticals’s yearly revenue?
Eton Pharmaceuticals's yearly revenue for 2023 was $31.64M, representing an increase of 48.90% compared to 2022. The company's yearly revenue for 2022 was $21.25M, representing a decrease of -2.66% compared to 2021. ETON's yearly revenue for 2021 was $21.83M, representing an increase of 55879.49% compared to 2020.
What is Eton Pharmaceuticals’s quarterly revenue?
Eton Pharmaceuticals's quarterly revenue for Q2 2024 was $9.07M, a 13.91% increase from the previous quarter (Q1 2024), and a -24.36% decrease year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $7.97M, a 8.93% increase from the previous quarter (Q4 2023), and a 50.19% increase year-over-year (Q1 2023). ETON's quarterly revenue for Q4 2023 was $7.31M, a 4.06% increase from the previous quarter (Q3 2023), and a -13.94% decrease year-over-year (Q4 2022).
What is Eton Pharmaceuticals’s revenue growth rate?
Eton Pharmaceuticals's revenue growth rate for the last 3 years (2021-2023) was 44.93%, and for the last 5 years (2019-2023) was 3199.48%.
What are Eton Pharmaceuticals’s revenue streams?
Eton Pharmaceuticals's revenue streams in c 23 are License, and Product Sales and Royalties. License generated $5.5M in revenue, accounting 17.38% of the company's total revenue Product Sales and Royalties generated $26.14M in revenue, accounting 82.62% of the company's total revenue
What is Eton Pharmaceuticals’s main source of revenue?
For the fiscal year ending Dec 23, the largest source of revenue of Eton Pharmaceuticals was Product Sales and Royalties. This segment made a revenue of $26.14M, representing 82.62% of the company's total revenue.